Medifast MED
- Market cap
- $140.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $299.6M
- −30% on a year ago
- Net margin
- −13.6%
- Free cash flow yield
- −2.8%
Medifast trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $299.6M over the last twelve months, down 30% on a year earlier with a −14% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $191M−43% | $174.7M−50% | $168.6M−43% | $140.2M−41% | $119M−38% | $115.7M−34% | $105.6M−37% | $89.4M−36% | $75.1M−37% | $76M−34% | $76.4M−28% | $72M−19% | |
| Cost of revenue | $49.6M−52% | $47.4M−54% | $45.1M−47% | $34.5M−41% | $30.8M−38% | $31.5M−34% | $28.9M−36% | $27.3M−21% | $23M−25% | $24.3M−23% | $23M−21% | $22M−19% |
| Gross profit | $141.4M−40% | $127.3M−48% | $123.4M−41% | $105.7M−40% | $88.2M−38% | $84.2M−34% | $76.6M−38% | $62.2M−41% | $52.1M−41% | $51.8M−39% | $53.4M−30% | $50M−20% |
| SG&A | $132.7M−34% | $119.4M−38% | $131.3M−24% | $103.6M−32% | $87.5M−34% | $85.5M−28% | $77.7M−41% | $66.2M−36% | $59.9M−32% | $55.1M−36% | $57.7M−26% | $69.4M+5% |
| $8.7M−73% | $7.9M−85% | −$7.9M | $2.1M−92% | $709K−92% | −$1.3M | −$1.1M−87% | −$4.1M | −$7.8M | −$3.3M+161% | −$4.3M+306% | −$19.4M+374% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | $9.8M−70% | $11.6M−78% | −$10.7M | $1.6M−94% | $1.3M−87% | $526K−96% | $2.9M | −$2.7M | −$6.4M | −$1.9M | −$3M | −$17.8M+571% |
| $3.8M−36% | $3.3M−76% | −$2.5M | $449K−87% | $474K−87% | $1.3M−60% | $395K | −$396K | $11.7M+2376% | $181K−86% | $109K−72% | −$324K−18% | |
| Net income | $6M−77% | $8.3M−79% | −$8.2M | $1.1M−95% | $801K−87% | −$772K | $2.5M | −$2.3M | −$18.1M | −$2.1M+175% | −$3.1M | −$17.5M+675% |
| $0.55−77% | $0.76−79% | −$0.75 | $0.10−95% | $0.07−87% | −$0.07 | $0.22 | −$0.21 | −$1.65 | −$0.19+171% | −$0.28 | −$1.57+648% | |
| 10.9M−1% | 11M+1% | 10.9M+0% | 11M+0% | 11M+1% | 10.9M−0% | 11.1M+1% | 11M+0% | 11M+0% | 11M+1% | 11.1M+1% | 11.2M+2% |
EPS, diluted: 11 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY10 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY14 and Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Packaged Foods nearest Medifast's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MEDMedifast | $140.1M | n/m | 23.3× | 0.5× | −30% | −13.6% | |
| LWAYLifeway Foods | $336.5M | 31.8× | 31.2× | 1.4× | +26% | 4.5% | |
| MAMAMama's Creations | $606.8M | 75.7× | 58.2× | 2.9× | +54% | 3.5% | |
| JVACoffee | $28.7M | 6.1× | 22.9× | 0.3× | +8% | 4.9% | |
| SENEASeneca Foods | $1.1B | 9.2× | 8.9× | 0.6× | +12% | 6.7% | |
| BRBRBellring Brands | $1.1B | 6.7× | 34.9× | 0.5× | +6% | 7.3% | |
| Peer median | $606.8M | 9.2× | 31.2× | 0.6× | +12% | 4.9% |
More on Medifast
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Packaged Foods
- Sector
- Consumer Defensive
Valuation data, not investment advice. Prices as of .